Drugs / PEP-DC2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05714306 | Aug 2023 → Mar 2030 | ovarian serous adenocarcinoma | Centre Hospitalier Universitaire Vaudois | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEP-DC2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05714306 ↗ |
| Modality | Cell therapy | “autologous dendritic cells pulsed with the peptides detected or predicted after vaccination with OC-DC” NCT05714306 ↗ |